Yingze Zhang

Yingze Zhang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2025 in Journal of Controlled Release
Verified
Journal Article
Closed access
XHXiaodong Hu
Xiaodong Hu
YCYujiong Chen
Yujiong Chen
JHJian Huang
Jian Huang
SDShuhang Dong
Shuhang Dong
KXKuishuai Xu
Kuishuai Xu
YZYingze Zhang
Yingze Zhang

20 May 2026 in Journal of Controlled Release
Verified
Journal Article
Closed access
XHXiaodong Hu
Xiaodong Hu
JHJian Huang
Jian Huang
SDShuhang Dong
Shuhang Dong
KXKuishuai Xu
Kuishuai Xu
MZMinzhe Zheng
Minzhe Zheng
YZYingze Zhang
Yingze Zhang

17 June 2026 in Phytomedicine
Verified
Journal Article
Open access
YZYang Zhang
Yang Zhang
SLShuanggong Liu
Shuanggong Liu
SDShuhang Dong
Shuhang Dong
GSGuangxu Song
Guangxu Song
KWKewen Wang
Kewen Wang
DWDongjin Wu
Dongjin Wu
Intervertebral disc degeneration (IVDD) is a major contributor to low back pain and is characterized by mitochondrial dysfunction, inflammation, and regulated cell death in nucleus pulposus (NP) cells. NLRP3 inflammasome-mediated pyroptosis plays a pivotal role in disc degeneration, whereas mitophagy limits mitochondrial damage and inflammasome activation. Emerging evidence indicates that pterostilbene (PTE) exhibits diverse pharmacological activities; however, its role in attenuating IVDD remains insufficiently understood. To investigate whether PTE attenuates IVDD by regulating mitophagy and NLRP3 inflammasome-mediated pyroptosis, and to elucidate the underlying molecular mechanisms. This study combined network pharmacology analysis, in vitro cellular experiments, and an in vivo rat IVDD model to evaluate the therapeutic effects and mechanisms of PTE. Network pharmacology was used to predict the cytoprotective potential of PTE. In vitro, LPS-stimulated NP cells were employed to evaluate inflammation, extracellular matrix degradation, pyroptosis, mitochondrial function, and mitophagic flux. Pharmacological inhibitors were used to interrogate mitophagy-dependent mechanisms, while Western blotting, co-immunoprecipitation, and related assays were performed to assess signaling pathways, protein stability, and ubiquitination. In vivo, a rat IVDD model was established to evaluate the therapeutic effects of PTE through radiological and histopathological analyses. PTE attenuated LPS-induced inflammatory responses and extracellular matrix degradation in NP cells. It suppressed NLRP3 inflammasome-mediated pyroptosis and restored mitochondrial function by enhancing mitophagic flux, whereas inhibition of mitophagy partially reversed these protective effects. Mechanistically, PTE activated the AMPK/mTOR/ULK1 signaling pathway to promote mitophagy. In parallel, PTE facilitated ubiquitination and proteasomal degradation of NLRP3, predominantly through K48-linked polyubiquitination, while K63-linked modification may contribute to regulatory signaling. Notably, this ubiquitination-mediated degradation occurred independently of mitophagy. In vivo, PTE significantly alleviated disc degeneration, reduced NLRP3, caspase-1, and p-mTOR expression, and increased collagen II, SOX9, PINK1, LC3, and p-AMPK levels. PTE attenuates IVDD progression by coordinately enhancing mitophagy and promoting K48-linked ubiquitin-proteasome-dependent degradation of NLRP3. These two mechanisms operate independently yet synergistically to suppress inflammasome activation, providing mechanistic insight into PTE as a potential disease-modifying therapeutic strategy for IVDD.

19 September 2026 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
YZYang Zhang
Yang Zhang
YGYucheng Gao
Yucheng Gao
SDShuhang Dong
Shuhang Dong
SLShuanggong Liu
Shuanggong Liu
LLLei Liu
Lei Liu
ZGZengxin Gao
Zengxin Gao
Intervertebral disc degeneration (IVDD) is a chronic degenerative disease with complex pathological mechanisms and a principal cause of low back pain world

6 November 2026 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
SDShuhang Dong
Shuhang Dong
ZWZehua Wang
Zehua Wang
YZYifan Zhuang
Yifan Zhuang
XHXiaodong Hu
Xiaodong Hu
SLShuanggong Liu
Shuanggong Liu
YZYingze Zhang
Yingze Zhang
Osteoarthritis (OA) is a heterogeneous whole-joint disease in which mechanical, inflammatory, metabolic, and age-related factors converge to disrupt tissue homeostasis. Mechanical loading is essential for cartilage maintenance, whereas excessive or insufficient mechanical stimulation may disrupt cartilage homeostasis depending on the loading modality, magnitude, frequency, duration, recovery conditions, and tissue context. In this review, we integrate OA mechanobiology across scales, from whole-joint load redistribution and tissue-level mechanical filtering to chondrocyte mechanosensing and intracellular responses. The mechanistic emphasis is on cartilage and chondrocytes within the broader whole-joint context of OA. We discuss how integrin-focal adhesion complexes, PIEZO1/2, TRPV4, primary cilia, the cytoskeleton, and nuclear mechanotransduction regulate matrix metabolism, mitochondrial redox homeostasis, autophagy and mitophagy, regulated cell death, and cellular senescence. We further highlight mechanical unloading, immobilization, and microgravity-related models as distinct experimental contexts and discuss epigenetic, epitranscriptomic, and ubiquitin-dependent regulation as potential mechanisms underlying persistent cellular reprogramming, while recognizing that mechanical memory after stimulus withdrawal remains insufficiently established in OA. Finally, we outline how subject-specific modeling, spatial multi-omics, joint-on-chip systems, and multimodal mechanical phenotyping may support mechanobiology-guided OA stratification and therapy. Restoring patient-specific mechanical homeostasis, rather than simply reducing loading, may provide a framework for precision management of OA.